March 1, 2025, Copenhagen: While our primary focus is rare diseases, our technology also has the potential to advance cancer research.
Our colleagues Gjorgji Madjarov and Marija Chausevska, as part of the COST Action 20116 research program, contributed to a groundbreaking study published in Seminars in Cancer Biology: “Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.”
This paper explores the critical role of epigenetic alterationsin pancreatic ductal adenocarcinoma (PDAC)—a highly aggressive cancer often diagnosed late, leading to poor prognosis.
A big thank you to Gjorgji and Marija for their dedication and contributions! And of course, to all the authors involved in this important research.
Read the full article here